Eversept Partners LP Buys 23,422 Shares of Liquidia Corporation $LQDA

Eversept Partners LP grew its stake in shares of Liquidia Corporation (NASDAQ:LQDA) by 4.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 509,443 shares of the company’s stock after purchasing an additional 23,422 shares during the period. Liquidia comprises about 0.9% of Eversept Partners LP’s investment portfolio, making the stock its 26th largest holding. Eversept Partners LP’s holdings in Liquidia were worth $17,571,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LQDA. NewEdge Advisors LLC bought a new stake in Liquidia during the 2nd quarter worth approximately $25,000. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the 4th quarter worth approximately $25,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Liquidia during the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC bought a new stake in Liquidia during the 3rd quarter worth approximately $34,000. Finally, Covestor Ltd increased its holdings in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares in the last quarter. 64.54% of the stock is owned by institutional investors.

Insider Transactions at Liquidia

In other news, CFO Michael Kaseta sold 139,390 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $40.14, for a total value of $5,595,114.60. Following the transaction, the chief financial officer owned 353,356 shares in the company, valued at $14,183,709.84. The trade was a 28.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen M. Bloch sold 318,893 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $50.23, for a total value of $16,017,995.39. Following the completion of the transaction, the director owned 1,870,042 shares in the company, valued at $93,932,209.66. The trade was a 14.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,282,894 shares of company stock worth $128,344,713 in the last 90 days. Insiders own 25.60% of the company’s stock.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $68.65 on Thursday. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $73.22. The stock’s 50 day moving average price is $51.76 and its 200-day moving average price is $41.76. The company has a market capitalization of $6.11 billion, a PE ratio of 490.39 and a beta of 0.58. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The business’s revenue was up 4187.1% compared to the same quarter last year. On average, equities analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on LQDA. BTIG Research boosted their price objective on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Wells Fargo & Company boosted their price objective on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. HC Wainwright boosted their price objective on Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, June 5th. Finally, Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $60.29.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).